NCT03603197View on ClinicalTrials.gov

BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

August 30, 2016

Study Completion Date

August 30, 2016

Conditions
Metastatic Breast CancerStage IV Breast Cancer
Interventions
DRUG

BP-C1

BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

DRUG

Placebo

Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days

Trial Locations (4)

41000

Udon Thani Cancer Hospital, Udon Thani

52000

Lampang Cancer Center, Lampang

Unknown

Siriraj Hospital, Mahidol University, Bangkok

Ubon Ratchanthani Cancer Hospital, Ubon Ratchathani

Sponsors

Lead Sponsor

Meabco A/S

Collaborators (1)

Meddoc
All Listed Sponsors
collaborator

Meddoc

OTHER

collaborator

Norwegian University of Life Sciences

OTHER

lead

Meabco A/S

INDUSTRY

NCT03603197 - BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter